<DOC>
	<DOCNO>NCT02734459</DOCNO>
	<brief_summary>Each patient randomize receive one dose test article one eye one dose reference formulation contralateral eye . One eye select initial eye cataract surgery aqueous humor collection hence dose operate first . Followed second eye dose early week follow aqueous humor collection per specify time point later 35 day follow first eye prior cataract surgery .</brief_summary>
	<brief_title>A Bioequivalence Study Compare Pharmacokinetics ( PK ) Of Marketed Product TobraDex® To An Experimental Ophthalmic Sterile Ointment Containing Tobramycin And Dexamethasone In Aqueous Humor In Patients Undergoing Indicated Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Be male female 18 year age Presence visually significant cataract eye Have chief complaint consistent visually significant cataract Be able communicate effectively study personnel able understand follow direction Be medically fit clinically acceptable laboratory profile ECG Be willing carry require pre op direction post op care able make schedule appointment Have give write informed consent participation study In addition , female patient child bear potential age must negative urine pregnancy test Participation ophthalmic indicative bioavailability/ bioequivalence/ Pharmacokinetic study receive ophthalmic indicative investigational drug within period three month prior screen Presence history recent viral corneal disorder active corneal condition contraindicate . Presence history uveitis uveitis Presence retinal disorder Ocular trauma within three month trial Patients receive topical systemic/ oral steroid Uncontrolled diabetes History allergy Known hypersensitivity allergy TobraDex® combination component Clinical laboratory test value outside acceptable reference range confirm reexamination deem clinically significant determine investigator ( ) Clinically significant illness 3 week prior Visit 1 ( determine investigator ) Presence clinically significant systemic disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>